Navigation Links
Independent Data Published on BioLife Solutions HypoThermosol® and CryoStor®
Date:1/27/2012

BOTHELL, Wash., Jan. 27, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer, and marketer of proprietary hypothermic storage and cryopreservation freeze media for cells and tissues, today announced that several groups of independent researchers have reported superior biopreservation efficacy using the Company's proprietary cGMP grade HypoThermosol storage/shipping medium and CryoStor cryopreservation freeze media.

(Logo:  http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Mike Rice, BioLife Chief Executive Officer, remarked on the growing body of evidence supporting broader adoption of the Company's products by stating, "We're very pleased to see additional independent research published on the unique advantages of our proprietary biopreservation media products. Our novel, engineered products are serum-free, protein-free, fully defined, and formulated to reduce preservation-induced cell damage and death.  With more than 300 customers, it's clear that we have successfully transitioned from early adoption to much broader preference and utilization of HypoThermosol and CryoStor."

The new journal articles include:

  • Evaluation of Bone Marrow-Derived MSC after Cryopreservation and Hypothermic Storage in Clinically Safe Medium, by researchers at Teva Pharmaceutical Industries Cell Therapy Lab, in Tissue Engineering, Part C: Methods.
  • About 95% of frozen cells were recovered as live cells after freezing in CryoStor solutions with 5% and 10% DMSO followed by storage in liquid nitrogen for 1 month 
  • Hypothermic storage for 2 and 4 days resulted in about 100% and 85% cell recovery respectively, less than 10% of apoptotic cells, and normal proliferation, marker expression, and osteogenic potential
  • Results demonstrate that human MSC could be successfully cryopreserved for banking and clinical applications and delivered to the bedside in clinically safe protective reagents
  • Hypothermic storage of isolated human hepatocytes: a comparison between University of Wisconsin solution and a hypothermosol platform, in Archives of Toxicology.
  • Cell viability, energy status, and xenobiotic metabolism following cold preservation in HypoThermosol was consistently and, in some cases, markedly higher when compared with other systems
  • Moreover, the use of HypoThermosol eliminates the need for serum in preservation solutions
  • HypoThermosol represents an improved solution compared to UW for extending the shipping/storage time of human hepatocytes
  • Additional published data by customers, which cite the use of BioLife include:

  • A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction, by the Duke Clinical Research Institute and several other centers, in the American Heart Journal.
  • Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous and placebo in patients with critical limb ischemia, in the Journal of Vascular Surgery.
  • Juvenile Chondrocytes May Facilitate Disc Repair, in The Open Tissue Engineering and Regenerative Medicine Journal.
  • An expanded bibliography of articles, posters, and abstracts citing applications and benefits of CryoStor and HypoThermosol can be found on BioLife's website.

    BioLife Solutions will be exhibiting and presenting at the Phacilitate Cell & Gene Therapy Forum 2012, January 30th – February 1st in Washington, DC.

    About BioLife Solutions
    BioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

    This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media Relations:Investor Relations: Len Hall

    Matt Clawson

     Allen & Caron Inc

    Allen & Caron Inc

     (949) 474-4300

    (949) 474-4300

     len@allencaron.com

    matt@allencaron.com

     


    '/>"/>
    SOURCE BioLife Solutions, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Aria Announces Publication of Independent Study in the American Journal of Obstetrics & Gynecology Using Arias Technology
    2. Parata Systems Announces Presenting Sponsorship of 2012 Independent Pharmacy Business Growth Conference
    3. Winner Medical Appoints BDO China as Independent Auditor
    4. NCPA Launches Initiative to Help Independent Community Pharmacies Create Better Business Opportunities for Front-End Merchandise
    5. Independent Laboratory Testing Demonstrates Important Quality Differences Between FDA-Approved Makena® and Compounded 17P Formulations
    6. Adeona Appoints Jeff Lucero Riley as Independent Chairman
    7. NCPA Digest Finds Independent Community Pharmacies Reducing Health Costs Through Generic Drug Use, Patient Counseling
    8. Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics Pixantrone PIX301 Pivotal Trial
    9. China Medicine Corporation Appoints PricewaterhouseCoopers As Independent Auditor To Audit Results For Fiscal Years 2006 - 2010
    10. New Report: Independent Drugstores Thrive in Economic Recession
    11. NeoStem Appoints Grant Thornton LLP as New Independent Registered Public Accounting Firm
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/24/2017)... 2017 A ReportsnReports.com report says, over the ... as the global sales of Adcetris and Kadcyla have been witnessing ... drug conjugates market is driven by large number of ADC drugs ... window offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major Company Profiles, ...
    (Date:3/24/2017)... INDIANAPOLIS , March 24, 2017  Eli ... today announced plans to invest $850 million in ... span facilities across its U.S. enterprise, including research ... The investments are being driven by demand for ... of potential medicines in development targeting cancer, pain, ...
    (Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA (OSE: ... complete 2016 Annual Accounts with notes. The report is attached ... the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, please ... Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media enquiries: ...
    Breaking Medicine Technology:
    (Date:3/25/2017)... ... ... Swissray is pleased to announce the release of the ELITE DXA, a new bone ... scan window, which is more than double that of existing bone densitometers. Historically, subjects ... an accurate total body bone density or body composition study. The ELITE DXA ...
    (Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
    (Date:3/24/2017)... Antonio, TX (PRWEB) , ... March 24, 2017 , ... ... new clinic which can be found at 9618 Huebner Road. The clinic is the ... PT, OCS, Clinic Director, and Dr. Ali Higgins, PT, will provide care from the ...
    (Date:3/24/2017)... ... March 24, 2017 , ... In just ... EcoQube Frame vertical micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone ... with nearly 2,000 consumers (and counting) already backing the campaign. , “We ...
    (Date:3/24/2017)... ... March 24, 2017 , ... The law firm of Enea, Scanlan ... to announce Westchester resident Lauren C. Enea has joined the firm as an associate ... concentrate her practice in elder law, Medicaid planning and applications, and Wills, Trusts and ...
    Breaking Medicine News(10 mins):